Dog arthritis and collagen: does it actually work?

Does your dog struggle to get up or hesitate on the stairs? Osteoarthritis is one of the most common joint disorders in senior dogs. Faced with this problem, many owners turn to dietary supplements such as collagen. But what does science really say? This article answers your questions based on recent studies and veterinary recommendations.

Collagen: a family of essential proteins

Collagen is the most abundant protein in the body. It represents nearly 30% of total protein and plays an essential role in the strength and flexibility of tissues. It is found in skin, bones, ligaments, tendons, cartilage, and even the cornea.

Contrary to what marketing suggests, there is not “one” collagen but more than 28 distinct types, identified by science:

• type I collagen predominates in skin, bones and tendons,
• type II collagen makes up the majority of articular cartilage,
• other types (III, IV, V…) contribute to the organisation of connective tissues.

It is type II collagen that interests us most for the joints of dogs with osteoarthritis, since it lies at the heart of cartilage structure.

Hydrolysed collagen (peptides)

Hydrolysed collagen is obtained by enzymatic hydrolysis, a process that breaks down long collagen fibres into small peptides. These peptides are short chains of amino acids, which are mini-proteins that are easier to absorb. They are rich in glycine, proline, and hydroxyproline (gly-pro-hyp). Amino acids are the building blocks of all the body's proteins, much like the letters that form words. These collagen fragments can cross the intestinal barrier, enter the bloodstream, and reach the tissues.

Proposed mechanism

In theory, hydrolysed collagen would act in several ways:

• It would supply essential amino acids, the “building blocks” used to maintain cartilage.
• It would stimulate cartilage cells, called chondrocytes, encouraging them to produce more collagen.
• It could inhibit certain destructive enzymes responsible for cartilage breakdown over time.
• Finally, it would slightly reduce inflammation, by limiting the production of inflammatory molecules.

Actual mechanism

In reality, these effects remain modest. Collagen peptides do not “repair” cartilage, but they may help maintain a more favourable balance between production and degradation.

Result: some dogs seem a little more supple or comfortable, without this reflecting true regeneration.

Veterinarians sometimes observe a slight improvement in comfort, but results vary greatly depending on the individual, the dose used and the duration of supplementation.

Clinical results

Several studies have evaluated hydrolysed collagen in arthritic dogs, with overall encouraging but still highly variable results.

Early work (Beynen 2010, Schunck 2017) reported improvements in stiffness and lameness, observed by owners or veterinarians. However, these trials were conducted with products supplied by the manufacturers themselves and without a true control group, which limits the reliability of the conclusions.

A more recent study (Eckert 2021) tested a higher dose and showed improved joint sensitivity, but without a clear reduction in chronic pain. Here again, industry co-funding raises doubts about the independence of the results.

Finally, the most robust study to date (Dobenecker 2024, University of Munich) evaluated a weight-adjusted dose (200 mg/kg). Treated dogs showed a measurable improvement in locomotion, although owners did not always perceive a visible difference in day-to-day comfort.

Overall, hydrolysed collagen shows potential for metabolic support of cartilage, but the effects remain modest and highly dependent on the doses tested, often far higher than those in products available on the market.

Limitations

• Highly variable doses: clinical studies range from 5 to 20 g/day fixed doses, or up to 200 mg/kg by body weight. Most commercial products (1–3 g/day) are therefore probably underdosed compared with trial protocols.
• Often subjective criteria: many assessments rely on owner questionnaires, which are sensitive to placebo effects and product expectations. Trials using objective measures (force plate, accelerometry) remain rare.
• Frequent industry bias: several positive studies were sponsored by collagen manufacturers. Only the recent Dobenecker study (2024) appears independent, making it a stronger reference.

In practice: hydrolysed collagen acts mainly as metabolic support for cartilage. It may offer functional benefits (mobility, comfort), but the evidence remains heterogeneous and dependent on study quality. Moreover, effective clinical doses are generally well above those offered in most supplements on the market.

Undenatured type II collagen

Undenatured type II collagen, unlike hydrolysed collagen, retains its original form along with the antigenic sites recognised by the immune system. This explains its particular mode of action.

Proposed mechanism

Undenatured type II collagen acts through a unique mechanism linked to the immune system. When taken in very small amounts (around 10 mg per day), it reaches the small intestine, where it comes into contact with Peyer's patches, small surveillance zones of the immune system.

Here's how it works:

• Recognition of collagen: its intact structure is identified by the body, which learns not to regard it as a threat.
• Oral tolerance: this “learning” process teaches the immune system to remain calm in the presence of joint collagen.
• Activation of regulatory cells: cells called regulatory T lymphocytes (or Treg) are stimulated.
• Calming effect: these Treg cells then circulate through the body and send calming signals to the joints, reducing inflammation and the production of inflammatory molecules.

Actual mechanism

In practice, undenatured type II collagen does not supply material to rebuild cartilage.

Its action is immunological: it helps calm the excessive inflammatory response in the joints.

The expected effect is a reduction in pain and stiffness, sometimes accompanied by improved mobility.

It is therefore not a “repair” product, but an immune system modulator.

Clinical results

Several studies have evaluated the efficacy of undenatured type II collagen in arthritic dogs, but most of them were industry-funded, which limits their scope.

• Early work (Deparle 2005, D'Altilio 2007) showed improvements in pain and lameness after 90 to 120 days of supplementation, alone or combined with glucosamine and chondroitin. These results should be interpreted cautiously, as the trials were sponsored by the manufacturer and relied on subjective assessments.
• A stronger study (Gupta 2012) confirmed better locomotion measured objectively by force plate, but again, funding came from the producing laboratory, which reduces scientific independence.
• More recent trials, such as Stabile et al. (2022), compared undenatured type II collagen with an anti-inflammatory (cimicoxib) over 30 days: both treatments produced similar results, but the duration was too short to draw conclusions about real long-term efficacy.
• Finally, field studies (Cabezas 2022) or preventive trials (Varney 2021–2022) suggest a positive effect on mobility and certain markers of joint degradation, without proving a lasting therapeutic effect.

Overall, existing data indicate interesting potential, but studies are short, often sponsored, and concern only the patented form of undenatured type II collagen.

Limitations

• Published data on undenatured type II collagen come almost exclusively from studies funded or supported by the laboratory.
• This creates a risk of bias: preferential publication of positive results, oriented interpretation.
• Moreover, the results concern only this patented product: they cannot be extrapolated to other undenatured collagens.

In practice: Type II collagen acts as an immune modulator. Clinical data are interesting and based on objective measures, but it is essential to bear in mind the industry bias inherent to this patented product.

What does veterinary science say about collagen?

Beyond individual trials, several research teams have attempted to synthesise the available data. This is the case with the meta-analysis by Barbeau-Grégoire et al. (2022), which reviewed joint supplements in dogs, including collagen.

Collagen trials vary widely in design, endpoints and formulations. Positive findings often come from small, industry-sponsored studies using unvalidated assessment tools.

Barbeau-Grégoire et al.

Key points highlighted by this meta-analysis:

• Lack of standardisation: variable doses (1 to 20 g/day or 200 mg/kg), different forms (hydrolysed, undenatured type II), short study durations (mostly 4 to 16 weeks).
• Often subjective criteria: based on owner assessment, sensitive to placebo effects. Few studies include objective measures such as force plate or validated scores (CBPI, LOAD).
• Frequent industry bias: most positive publications come from teams linked to manufacturers.
• Encouraging but unconfirmed results: some studies show improvements in locomotion or limb loading, but results are far from uniform.

Current scientific data do not allow a conclusion of robust and generalisable efficacy of collagen in canine osteoarthritis. Interesting signals are observed, but insufficient methodological quality and dependence on sponsors greatly limit the confidence that can be placed in these results.

What better-documented alternatives to collagen?

While collagen is attracting growing interest, the scientific literature emphasises that its evidence remains fragile and heterogeneous, particularly because of numerous industry biases and variability in tested doses.

The question therefore arises naturally: what are the most solid active ingredients for supporting a dog's joints?

The meta-analysis by Barbeau-Grégoire et al. (2022), which compared all nutraceuticals available for dogs, highlights two families whose efficacy is best demonstrated:

• Omega-3 fatty acids (EPA and DHA): widely studied, with several independent trials. They reduce joint inflammation and improve mobility, particularly when used in concentrated, bioavailable forms.
• Green-lipped mussel extract from New Zealand (Perna canaliculus): rich in omega-3 fatty acids and other anti-inflammatory compounds, including antioxidants. Several studies have shown an improvement in clinical signs of osteoarthritis in dogs.

Omega-3 (EPA/DHA) and New Zealand green lipped mussel are the ingredients with the strongest veterinary evidence for canine osteoarthritis care.

Barbeau-Grégoire et al.

By comparison, data on collagen remain exploratory. It may be a supplement of interest, but should not be considered a first-line solution.

Conclusion

Collagen, in its various forms, is attracting growing interest for joint support in dogs. Yet available clinical data remain fragile, marked by industry bias and strong methodological heterogeneity. Positive signals are observed, but insufficient to make it a first-line solution.

Conversely, the veterinary literature is much stronger on two families of active ingredients: omega-3 fatty acids (EPA and DHA) and New Zealand green-lipped mussel oil, for which the evidence supporting effects on pain and mobility is stronger.

This combination is what distinguishes PERNIXOL®. This liquid supplement, developed by Laboratoire Sensilia, combines concentrated green-lipped mussel oil and algae oil rich in DHA. Its highly concentrated liquid form provides a concentrated source of marine omega-3 fatty acids to support joint comfort.

In summary: while collagen remains an option worth monitoring, omega-3 fatty acids and green-lipped mussel represent today's most reliable solutions to help your arthritic dog regain mobility and quality of life.

Scientific references

• Lugo JP, Saiyed ZM, Lau FC, Molina JP, Pakdaman MN, Shamie AN, Udani JK. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013 Oct 24;10(1):48. doi: 10.1186/1550-2783-10-48. PMID: 24153020; PMCID: PMC4015808.
• Barbeau-Grégoire, M.; Otis, C.; Cournoyer, A.; Moreau, M.; Lussier, B.; Troncy, E. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. Int. J. Mol. Sci. 2022, 23, 10384. https://doi.org/10.3390/ijms231810384
• Beynen AC, Van der Vlerk T, Van Diepen H, et al. (2010). Oral administration of collagen hydrolysate reduces clinical signs of osteoarthritis in dogs. Tijdschrift voor Diergeneeskunde, 135(8): 278–282.
• Cabezas MÁ, Benito J, Ortega Á, Garcia-Pedraza E. Long-term supplementation with an undenatured type-II collagen (UC-II®) formulation in dogs with degenerative joint disease: Exploratory study. Open Vet J. 2022 Jan-Feb;12(1):91-98. doi: 10.5455/OVJ.2022.v12.i1.11. Epub 2022 Feb 5. PMID: 35342740; PMCID: PMC8956235..
• D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, Gupta RC, Canerdy TD, Goad JT, Bagchi M, Bagchi D. Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. Toxicol Mech Methods. 2007;17(4):189-96. doi: 10.1080/15376510600910469. PMID: 20020968.
• Deparle LA, Gupta RC, Canerdy TD, Goad JT, D'Altilio M, Bagchi M, Bagchi D. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J Vet Pharmacol Ther. 2005 Aug;28(4):385-90. doi: 10.1111/j.1365-2885.2005.00668.x. PMID: 16050819.
• Dobenecker B, Böswald LF, Reese S, Steigmeier-Raith S, Trillig L, Oesser S, Schunck M, Meyer-Lindenberg A, Hugenberg J. The oral intake of specific Bioactive Collagen Peptides (BCP) improves gait and quality of life in canine osteoarthritis patients-A translational large animal model for a nutritional therapy option. PLoS One. 2024 Sep 19;19(9):e0308378. doi: 10.1371/journal.pone.0308378. PMID: 39298537; PMCID: PMC11412516.
• Eckert T, Jährling-Butkus M, Louton H, Burg-Roderfeld M, Zhang R, Zhang N, Hesse K, Petridis AK, Kožár T, Steinmeyer J, Schauer R, Engelhard P, Kozarova A, Hudson JW, Siebert HC. Efficacy of Chondroprotective Food Supplements Based on Collagen Hydrolysate and Compounds Isolated from Marine Organisms. Mar Drugs. 2021 Sep 26;19(10):542. doi: 10.3390/md19100542. PMID: 34677442; PMCID: PMC8541357.
• Gupta RC, Canerdy TD, Lindley J, Konemann M, Minniear J, Carroll BA, Hendrick C, Goad JT, Rohde K, Doss R, Bagchi M, Bagchi D. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. J Anim Physiol Anim Nutr (Berl). 2012 Oct;96(5):770-7. doi: 10.1111/j.1439-0396.2011.01166.x. Epub 2011 May 30. PMID: 21623931.
• Schunck, M., Louton, H. and Oesser, S. (2017) The Effectiveness of Specific Collagen Peptides on Osteoarthritis in Dogs-Impact on Metabolic Processes in Canine Chondrocytes. Open Journal of Animal Sciences, 7, 254-266. https://doi.org/10.4236/ojas.2017.73020
• Stabile M, Lacitignola L, Samarelli R, Fiorentino M, Crovace A, Staffieri F. Evaluation of clinical efficacy of undenatured type II collagen supplementation compared to cimicoxib and their association in dogs affected by natural occurring osteoarthritis. Res Vet Sci. 2022 Dec 10;151:27-35. doi: 10.1016/j.rvsc.2022.06.030. Epub 2022 Jul 10. PMID: 35853328.
• Varney JL, Fowler JW, Coon CN. Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy Labrador Retrievers during an exercise regimen. Transl Anim Sci. 2021 May 10;5(2):txab084. doi: 10.1093/tas/txab084. PMID: 34124592; PMCID: PMC8191485.
• Varney JL, Fowler JW, Coon CN. Impact of supplemented undenatured type II collagen on pain and mobility in healthy Labrador Retrievers during an exercise regimen. Transl Anim Sci. 2022 Aug 27;6(3):txac123. doi: 10.1093/tas/txac123. PMID: 36172458; PMCID: PMC9512092.
• Zapata, A.; Fernández-Parra, R. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. Animals 2023, 13, 870. https://doi.org/10.3390/ani13050870

This article was written by the R&D team at Laboratoire Sensilia, experts in animal nutrition.